RespireRx Pharmaceuticals Inc. (RSPI)
| Previous Close | 0.0009 |
| Open | 0.0009 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.0009 - 0.0010 |
| 52 Week Range | 0.0006 - 0.0191 |
| Volume | |
| Avg. Volume | 8,536,936 |
| Market Cap | 471,741 |
| Beta (5Y Monthly) | 0.53 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
GlobeNewswireRespireRx Pharmaceuticals Inc. Reports Publication of Preclinical Research Results Demonstrating the Ability of CX1739, its Lead Clinical AMPAkine, to Improve Bladder Function After Spinal Cord Injury
Glen Rock, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that, as part of an ongoing collaboration, a scientist team led by Dr. David Fuller of the University of Florida has published a peer-reviewed research article describing the ability of CX173
- GlobeNewswire
RespireRx Pharmaceuticals Inc. Reports Preclinical Pain Relief for their Non-Opioid Lead GABAkine
Glen Rock, N.J., Feb. 13, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce that KRM-II-81, its lead GABAA receptor potentiator (GABAkine), has advanced to the next level of evaluation within the NIH HEAL Initiative® Preclinical Screening Platform for Pain (PSPP) pro
GlobeNewswireRespireRx Pharmaceuticals Inc. Announces the Appointment of Dr. Dariusz Naziek to Its Board of Directors
Glen Rock, N.J., Jan. 22, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Market:RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is pleased to announce the appointment of Dr. Dariusz Nasiek MD, MBA to its board of directors. Dr. Nasiek is a dedicated anesthesiologist with expertise in anesthesiology and interventional pain management. Dr. Nas
